Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)
Emily Hinchcliff,Ami Patel,Bryan Fellman,Ying Yuan,Manoj Chelvanambi,Jen Wargo,YAN LIU,Jinsong Liu,Sanghoon Lee,Jason Roszik,Robert Hillman,Shannon Westin,Anil Sood,Pamela Soliman,Michael Frumovitz,Aaron Shafer,Larissa Meyer,Nicole Fleming,David Gershenson,David Vining,Dhakshina Ganeshan,Patrick Hwu,Karen Lu,Amir Jazaeri
DOI: https://doi.org/10.1016/s0090-8258(22)01325-7
IF: 5.304
2022-08-01
Gynecologic Oncology
Abstract:Objectives: Response rates to immune checkpoint inhibitors (ICI) in recurrent ovarian cancer have been disappointingly low. While emerging data suggest increased activity in patients with ovarian clear cell carcinomas (OCCC), only a minority of patients benefit even among this group. The objective of the current study was to investigate correlates of long-term survival in patients with OCCC treated with ICI. Methods: A review of medical records identified 28 patients with ovarian/peritoneal clear cell carcinoma who had been treated with CTLA4 and PD1/L1 ICI immunotherapy as part of two prospective RCTs. All patients except one received tremelimumab and durvalumab, either sequentially or in combination, and one additional patient received ipilimumab and nivolumab. Clinical-pathologic and tumor somatic mutation information (obtained from clinical next-generation sequencing) were correlated with overall survival (OS) using Kaplan-Meier and log-rank methodologies. Results: The evaluable patients were heavily pre-treated, with 1-9 prior lines of therapy (median: 2). The most common mutations were ARID1A (72%), PIK3CA (57%), and PPP2R1A (25%). The overall survival was significantly longer in patients whose tumors harbored a PPP2R1A hotspot mutation (n=7) compared to those without such mutation (n=21; median OS not reached vs 6.4 months, respectively, p=0.018; HR: 0.13 [95% CI: 0.02-0.95]; Figure 1). PPP2R1A mutations were also associated with more severe (≥grade 3) immune-related adverse events (57.1% vs 9.5% for non-carriers p=0.021). PPP2R1A mutations retained their prognostic significance within the subgroup of patients with ARID1A mutations (p=0.018). However, among patients without PPP2R1A mutations, there was no association between ARID1A mutations and OS (p=0.253). Increased survival resulted from prolonged stable disease and delayed responses, often following initial progression by RECIST v1.1. Fig. 1 Conclusions: These preliminary data suggest that PPP2R1A (rather than ARID1A) mutations may serve as a biomarker for long-term survival after ICI in OCCC, and ongoing research is aimed at determining a causal relationship. Given the benefit was delayed and often followed initial progression, harboring PPP2R1A mutations on ICI treatment beyond progression in patients with OCCC may be a consideration after appropriate counseling.
oncology,obstetrics & gynecology